Drug Profile
PAN 90806
Alternative Names: CP-547,632; CP-632; OSI-632; PAN-90806Latest Information Update: 23 Jun 2021
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals; Pfizer
- Developer PanOptica; Pfizer
- Class Antineoplastics; Eye disorder therapies; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
- No development reported Diabetic retinopathy
- Discontinued Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 16 Oct 2019 PAN 90806 is available for licensing as of 16 Oct 2019. www.panopticapharma.com
- 11 Oct 2019 Topline efficacy and adverse events data from a phase-I/II trial in Wet age-related macular degeneration released by PanOptica
- 11 Oct 2019 PanOptica plans pivotal trials for Wet age-related macular degeneration